Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
) pushed the Services sector higher today making it today's featured services winner. The sector as a whole closed the day down 1.5%. By the end of trading, Myriad Genetics rose $0.49 (1.9%) to $26.24 on average volume. Throughout the day, 2,107,928 shares of Myriad Genetics exchanged hands as compared to its average daily volume of 1,902,600 shares. The stock ranged in a price between $25.00-$26.55 after having opened the day at $25.56 as compared to the previous trading day's close of $25.75. Other companies within the Services sector that increased today were:
), up 61.1%,
), up 12.7%,
), up 7.2% and
), up 6.4%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.1 billion and is part of the diversified services industry. The company has a P/E ratio of 16.7, below the S&P 500 P/E ratio of 17.7. Shares are down 3.9% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Myriad Genetics a buy, 1 analyst rates it a sell, and 7 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Myriad Genetics Ratings Report.
On the negative front,
Digital Domain Media Group
), down 40.9%,
), down 40.9%,
), down 20.6% and
), down 13.0% , were all laggards within the services sector with
) being today's services sector laggard.
- Use our services section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the services sector could consider
) while those bearish on the services sector could consider
- Find other investment ideas from our top rated ETFs lists.
3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.